TY - JOUR
T1 - Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure
AU - Durand, Nisha
AU - Mallea, Jorge
AU - Zubair, Abba C.
N1 - Funding Information:
We would like to thank the Mayo Clinic Center for Regenerative Medicine for funding support.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the end of 2019 in Hubei province China, is now the cause of a global pandemic present in over 150 countries. COVID-19 is a respiratory illness with most subjects presenting with fever, cough and shortness of breath. In a subset of patients, COVID-19 progresses to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), both of which are mediated by widespread inflammation and a dysregulated immune response. Mesenchymal stem cells (MSCs), multipotent stromal cells that mediate immunomodulation and regeneration, could be of potential benefit to a subset of COVID-19 subjects with acute respiratory failure. In this review, we discuss key features of the current COVID-19 outbreak, and the rationale for MSC-based therapy in this setting, as well as the limitations associated with this therapeutic approach.
AB - The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at the end of 2019 in Hubei province China, is now the cause of a global pandemic present in over 150 countries. COVID-19 is a respiratory illness with most subjects presenting with fever, cough and shortness of breath. In a subset of patients, COVID-19 progresses to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS), both of which are mediated by widespread inflammation and a dysregulated immune response. Mesenchymal stem cells (MSCs), multipotent stromal cells that mediate immunomodulation and regeneration, could be of potential benefit to a subset of COVID-19 subjects with acute respiratory failure. In this review, we discuss key features of the current COVID-19 outbreak, and the rationale for MSC-based therapy in this setting, as well as the limitations associated with this therapeutic approach.
UR - http://www.scopus.com/inward/record.url?scp=85093947623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093947623&partnerID=8YFLogxK
U2 - 10.1038/s41536-020-00105-z
DO - 10.1038/s41536-020-00105-z
M3 - Review article
AN - SCOPUS:85093947623
SN - 2057-3995
VL - 5
JO - npj Regenerative Medicine
JF - npj Regenerative Medicine
IS - 1
M1 - 17
ER -